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Abstract
Rosacea is a common chronic inflammatory cutaneous disorder with variable presen‐
tation and severity. Disease usually occurs between the ages of 30 and 50 years. Women
are  more  commonly  affected  than  men.  Rosacea  is  divided  into  four  subtypes:
erythematotelangiectatic,  papulopustular,  phymatous,  and ocular,  and one variant:
lupoid or granulomatous rosacea. Erythematotelangiectatic rosacea is manifested as
flushing and persistent centrofacial erythema, and papulopustular rosacea as papules
and pustules in a centrofacial distribution. With disease progression, phymas consisting
of sebaceous gland hypertrophy can develop. Ocular rosacea can result in blepharitis
and conjunctivitis.  Diagnosis is made clinically. Management of rosacea consists of
protective measures such as sun protection and gentle skin care and topical and systemic
treatments to suppress inflammation and erythema.
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1. Introduction
Rosacea is a common chronic inflammatory cutaneous disorder with variable presentation and
severity. Facial flushing, telangiectasia, papules, and pustules are the main features of cutaneous
rosacea.
2. Epidemiology
Rosacea can be seen in any age, but the onset usually occurs between the ages of 30 and
50 years. Women are more commonly affected than men; however, the development of
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phymatous skin changes is more commonly observed in men. Although the disease is
more common in fair‐skinned people of Celtic origin, patients of any ethnic group can be
affected [1]. Up to 1/3 of the patients report a family history [2]. Rhinophyma, bulbous
nose due to increased connective tissue and hyperplastic sebaceous glands, is almost ex‐
clusively seen in men over 40 years of age [3]. The prevalence is highly variable as the
methods used and the populations studied vary greatly from one study to another [4]. A
Swedish study reported a prevalence of 10% with a female‐to‐male ratio of 3:1 [5]. Eye
involvement may be observed in more than 50% of patients [1].
3. Pathogenesis
Pathogenesis of rosacea is not well understood. Abnormalities in innate immunity, role of
cutaneous microorganisms, and UV damage and vascular dysfunction may play a role in
pathogenesis of rosacea.
Recent studies have shown the dysregulation of innate immune response in rosacea. Due to
an exacerbated innate immune response, patients develop inflammatory reactions to stimuli
that do not affect normal individuals. Patients with rosacea have high levels of cathelicidin, an
antimicrobial peptide with vasoactive and proinflammatory properties and local protease
kallikrein 5 (KLK5), which controls the production of cathelicidin peptides in epidermis.
Injection of mouse skin with cathelicidin peptides from patients with rosacea led to skin
changes similar to those observed in rosacea confirming the hypothesis [6]. Toll‐like receptors
(TLRs) work by triggering inflammation in response to recognized microbial patterns and
elevated TLR2 activity, leading to an increase in KLK5 level which may also contribute to
enhanced inflammatory responses responsible for rosacea signs [7].
Some microorganisms have been proposed to stimulate inflammatory reaction in cutaneous
rosacea. Demodex folliculorum is an obligatory parasite found in pilosebaceous unit. Although
almost all adults are infested with Demodex, patients with rosacea have increased density of
Demodex mites supporting a significant association between Demodex infestation and the
development of rosacea [8]. Correlation of gastrointestinal Helicobacter pylori infection and
rosacea is controversial. The prevalence of H. pylori infection is shown to be increased or not
different in patients with rosacea compared to control subjects. Treatment of H. pylori infection
with antibiotics has been shown to improve rosacea, but this may be the benefit of anti‐
inflammatory effects of the antibiotics used for treatment [9].
UV and sun exposure are among the exacerbating factors for rosacea. UV‐B has been shown
to induce cutaneous angiogenesis in mice. In skin, UV‐B increases vascular endothelial growth
factor (VEGF) and fibroblast growth factor 2 (FGF2) secretion from human keratinocytes
promoting angiogenesis. UV irradiation also produces reactive oxygen species, causing a
damage in dermal matrix and thus leading to inflammation [6].
Vascular hyperreactivity may also play a role in disease pathogenesis. Dermal expression of
VEGF, CD31, and lymphatic endothelium marker D2‐40 has been shown to be elevated in
rosacea, leading to stimulation of vascular and lymphatic endothelial cells [10].
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4. Classification and clinical features
Rosacea is manifested as erythematous flushing, papules, and pustules in a centrofacial
distribution. Intermittent or chronic facial edema may also occur. With disease progression,
some patients may develop yellow‐orange plaques called phymas consisting of sebaceous
gland hypertrophy [11].
There are four stages: pre‐rosacea and stages I through III. Patients with frequent flushing are
considered in pre‐rosacea group. In stage I, there is erythema that lasts from hours to days and
telangiectasias. In stage II, persistent erythema is accompanied by multiple inflammatory
papules and pustules. In stage III, large inflammatory nodules and connective tissue hyper‐
plasia occur [4] (Table 1).
Pre-rosacea Frequent flushing
Stage 1 Transient facial erythema that becomes more persistent telangiectasias
Stage 2 Persistent facial erythema
Papules, pustules
Ocular changes
Stage 3 Large inflammatory nodules
Tissue hyperplasia, fibroplasias
Table 1. Stage symptoms and signs [11].
The National Rosacea Society (NRS) has classified rosacea into four subtypes: erythematote‐
langiectatic, papulopustular, phymatous, and ocular, and one variant: lupoid or granuloma‐
tous rosacea.
4.1. Erythematotelangiectatic type
The erythematotelangiectatic type is the most common subtype of rosacea (Figure 1). It is
characterized by flushing and persistent central facial erythema with sparing of periocular
skin. The flushing of rosacea lasts longer than 10 min differentiating it from physiological
flushing episodes. Telangiectasias are common but not essential for the diagnosis of this
subtype. Stinging or burning sensations may be present [4].
4.2. Papulopustular type
Papulopustular rosacea is characterized by persistent central facial erythema: small, dome‐
shaped erythematous papules and surmounting pustules on the central face [4] (Figure 2).
However, papules and pustules may also occur periorificially. The inflammation seen in
papulopustular rosacea is similar to acne vulgaris, but comedones typical for acne vulgaris are
absent in rosacea [12].
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In a study, 15 patients with pustular rosacea and 15 age‐ and sex‐matched control subjects were
compared. A significantly increased growth of S. epidermidis was found in rosacea pustules
and eyelid margins of rosacea patients suggesting a role of S. epidermidis in pathogenesis of
pustular and ocular rosacea [13].
Figure 1. Erythematotelangiectatic type of rosacea. Prominent telangiectatic vessels and erythema on the cheek with
characteristic sparing of periocular skin.
Figure 2. Papulopustular type of rosacea. Extensive papules and pustules on a background of persistent erythema.
4.3. Ocular rosacea
Ocular rosacea occurs in more than 50% of patients with rosacea. Eye involvement may follow,
as seen in half of the patients, may precede as in 20%, or occur simultaneously with skin
changes [12].
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Patients with ocular rosacea may complain of foreign body sensation, dryness, itching,
photophobia, and tearing. If the cornea is involved by the disease, the visual acuity may be
decreased [14]. Blepharitis and conjunctivitis are the most common findings. Blepharitis is
characterized by the eyelid margin erythema, scale, and staphylococcal infections. Hypopyon,
scleritis, keratitis, and iritis can also occur. Rosacea keratitis is a severe condition and has a
poor prognosis. It can lead to corneal opacity, scarring, and loss of vision. The severity of ocular
rosacea symptoms is often not related to the severity of cutaneous manifestations [4].
4.4. Phymatous rosacea
Phymatous rosacea shows tissue hypertrophy manifesting as thickened skin with irregular
contours and prominent pores. Involvement most commonly occurs on the nose (rhinophyma),
but the chin (gnathophyma), forehead (metophyma), and ears (otophyma) may also be affected
[4]. Rhinophyma occurs mostly in men with a male/female ratio of 20:1. Although rhinophyma
is often accepted as a presentation of last stage of rosacea, it may occur in patients with few or
no other features of rosacea. One diagnosis is a clinical one, and biopsy is only indicated to
rule out alternative diagnoses or in suspicion of a malignancy such as basal cell carcinoma or
squamous cell carcinoma [15].
4.5. Granulomatous rosacea
Granulomatous rosacea was classified by the expert committee as a disease variant charac‐
terized by discrete yellow, brown, red papules, or nodules on periorificial facial skin [12]
(Figure 3). Patients do not often have persistent erythema or flushing of the face and may
not have their disease distributed to convexities of the face [16].
Figure 3. Granulomatous rosacea. Discrete yellow papules clustered periorficially.
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5. Histopathology
In mild forms of rosacea, histologic findings are often limited to vascular ectasia and mild
edema. A lymphohistiocytic infiltrate with perivascular and perifollicular distribution is
observed in papulopustular form [17]. Solar elastosis is invariably found in histopathologic
examination of biopsy specimens. In granulomatous variant, non‐caseating epithelioid
granulomas are seen within the dermis [18].
6. Diagnosis and differential diagnosis
Diagnosis of rosacea is made clinically; there is no laboratory test to confirm the diagnosis. A
biopsy is only indicated to rule out alternative diagnoses [1] (Table 2).
Acne vulgaris
Seborrheic dermatitis
Keratosis pilaris
Dermatomyositis
Systemic lupus erythematosus
Photodermatitis
Sarcoidosis
Demodicosis
Haber syndrome
Basal cell carcinoma
Table 2. Differential diagnosis of facial rosacea [17, 19].
Acne vulgaris is the disease most commonly confused with rosacea, especially in middle‐aged
adults. Key distinguishing feature between acne vulgaris and rosacea is the absence of
comedones in rosacea [4]. Patients with acne vulgaris are often younger patients, having oily
skin with comedones, larger pustules, and less erythema with scarring [1].
Perioral dermatitis presents with micropustules and vesicles with scaling around the mouth.
Seborrheic dermatitis often coexists with rosacea [17]. Scaling and erythema of the scalp,
eyebrows, external auditory canals, and retroauricular folds serve as clues to the presence of
seborrheic dermatitis [4].
The malar erythema of systemic lupus erythematosus can be difficult to distinguish from
rosacea. Clinically, papules pustules and ocular symptoms are mostly absent in lupus [17].
Severe Demodex infection (demodicosis) may present with rosacea‐like features, but flushing
and telangiectasia are absent [4]. And also, photodermatitis is triggered by sun exposure and
has similar skin manifestations to rosacea [4].
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7. Associated diseases
Rosacea patients may have increased risk of developing certain diseases as evidenced by case‐
controlled studies. Further studies are necessary to confirm these associations.
Patients with rosacea are more likely to have dyslipidemia and hypertension. They are also at
increased risk of coronary artery disease after adjustment for cardiovascular disease risk
factors [20]. There is a possible association between rosacea and an increased risk of thyroid
cancer and basal cell carcinoma [21].
Rosacea was associated with a significantly increased risk of glioma in a Danish nationwide
cohort [22]. In the same Danish cohort, patients with rosacea had an increased risk of autoim‐
mune diseases, including type 1 diabetes mellitus, celiac disease, multiple sclerosis, and
rheumatoid arthritis [23].
8. Treatment
8.1. Protective measures
Protective measures are of utmost importance in management of rosacea patients of all
subtypes. These include avoidance of triggers of flushing, gentle skin care, and sun protection.
Most sufferers report worsening of the disease by factors such as hot or cold temperature, wind,
hot drinks, exercise, spicy food, alcohol, emotions, and menopause [24]. A variety of medica‐
tions may exacerbate flushing such as vasodilative drugs, nicotinic acid and amyl nitrite,
calcium channel blockers, and opiates [1].
Cleansers containing acetone or alcohol should be avoided. Usage of abrasive or exfoliant
preparations and vigorous rubbing of the skin should also be discontinued [1].
Daily application of combined ultraviolet‐A and ultraviolet‐B protective sunscreen with a sun
protection factor of 15 or greater should be advised to every patient. Sun‐blocking creams
containing titanium dioxide and zinc oxide are usually well tolerated [1].
8.2. Erythematotelangiectatic rosacea
Erythematotelangiectatic rosacea is the most treatment‐resistant subtype of rosacea. Flushing
and burning are the most difficult features to treat. Non‐cardioselective β‐blockers such as
propranolol 40 mg twice daily or nadolol 40 mg daily can be tried, but provide rather limited
benefit [25].
Topical or oral medications described below for papulopustular rosacea are often used, but
evidence supporting their role in erythematotelangiectatic rosacea is lacking [1].
Treatment of erythema and telangiectasia with vascular lasers or intense pulse light can help
in improving flushing and burning [4].
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8.3. Papulopustular rosacea
Systemic and topical antibiotics are effective in treatment of papulopustular rosacea. Patients
with moderate‐to‐severe papulopustular rosacea at initial presentation may require systemic
therapy to achieve clearance of inflammatory skin lesions followed by topical treatment to
avoid relapses. Topical medications alone can be used to control milder disease.
Main topical agents utilized for the treatment of rosacea include metronidazole, sulfacetamide‐
sulfur, azelaic acid, and topical antibiotics (clindamycin, erythromycin) [26]. Three varieties of
0.75% metronidazole and 1% metronidazole and several brands of 10% sodium sulfacetamide
with 5% sulfur and 15% azelaic acid gel are medications that have been approved by the Food
and Drug Administration (FDA) for rosacea. All are indicated for the papules, pustules, and
erythema [4].
Topical metronidazole used once or twice daily is effective in treatment of inflammatory
papules and pustules and improving erythema of papulopustular rosacea. Azelaic acid is a
well‐tolerated preparation that also reduces papules and pustules. It is available in 15% gel
and 20% cream forms, applied twice a day; 10% sodium sulfacetamide with 5% sulfur is used
to treat acne, rosacea, and seborrheic dermatitis. It has beneficial effects in reducing both
inflammatory lesion counts and erythema scores in papulopustular rosacea [27]. Topical
erythromycin used for acne vulgaris can help in reducing symptoms but may prove irritant
on skin affected by rosacea [24]. Clindamycin gel, also developed for treatment of acne, may
be better tolerated. A combined formulation containing 5% benzoyl peroxide and 1% clinda‐
mycin has proved effective and well tolerated in a placebo‐controlled trial [4].
Topical retinoids have been used to treat rosacea, but the true efficacy has not been established.
Adapalen, a relatively well‐tolerated retinoid, has been shown to be an alternative treatment
agent in management of papulopustular rosacea [28].
Effective systemic antibiotics include tetracyclines (e.g., tetracycline or oxytetracycline 250 mg
twice daily) and erythromycin 250 mg twice daily. Second‐generation tetracyclines, such as
minocycline and doxycycline, are also effective and offer the advantages of once daily
administration and less gastrointestinal side effects [24]. Doxycycline shows anti‐inflamma‐
tory effects at doses as low as 40 mg daily [29]. Azithromycin was proven to be as effective as
doxycycline in a number of studies [4]. In one series, azithromycin proved beneficial after 4
weeks at 250 mg/day, for 3 days each week (Monday, Wednesday, and Friday) [30].
Oral metronidazole is an effective alternative treatment for rosacea. Metronidazole (200 mg)
taken twice daily for 12 weeks has been proved to be as effective in improving the inflammatory
lesions of rosacea as 250 mg oxytetracycline taken twice daily [4]. Abstinence from alcohol
during metronidazole therapy is necessary to avoid disulfiram‐like reactions. Although
relatively safe, metronidazole has been associated with potential side effects such as neuro‐
pathy and seizures [24].
Oral isotretinoin is a treatment option for severe rosacea. The onset of action of systemic
retinoids  is  slow when compared with  the  oral  antibiotics.  It  is  effective  both  in  eryth‐
ematotelangiectatic  and  papulopustular  rosacea.  Oral  istotretinoin  can  also  be  used  for
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granulomatous  rosacea  and  rhinophyma.  It  has  been  shown that  treatment‐resistant
patients  taking  isotretinoin  experienced  fewer  papules  and  pustules,  a  reduction  in
erythema,  and  decreased  nasal  volume  [31].  Daily  doses  of  isotretinoin  range  from  0.2
to  1  mg/kg.  It  is  usually  given  for  6  months.  With  low  dose  therapy,  the  common
mucosal  side  effects  of  the  drug  are  minimal  and  tolerable.  However,  due  to  its  tera‐
togenic  effects,  it  is  contraindicated  in  women of  childbearing  potential  [4].
8.4. Ocular rosacea
Treatment of ocular rosacea depends on disease severity. Lid hygiene and warm compresses
are the baseline treatment for all patients. For mild ocular rosacea, fucidic acid preparations
and metronidazole gel are frequently used [4]. Systemic antibiotics such as oral tetracyclin or
doxycyclin may be used in patients with a more severe involvement [32]. The keratitis
associated with rosacea can be severe, and patients with potentially serious ocular symptoms
should be referred to an ophthalmologist.
8.5. Rhinophyma
In patients with early rhinophyma, medical treatment with systemic isotretinoin may prove
beneficial. In advanced cases, surgery is performed. Surgery can be done either as a complete
excision or an incomplete excision made by cryosurgery, dermabrasion, electrosurgery, sharp
blade excision, shaving with a razor, or laser surgery [32].
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